Humanized monoclonal antibody against HER2/ERBB2; binds the extracellular domain of HER2 to inhibit receptor signaling and proliferation, and recruits immune effector functions to mediate antibody‑dependent cell‑mediated cytotoxicity (ADCC) against HER2‑overexpressing tumor cells.
YES
DIRECT
Binds HER2 on tumor cells and engages FcγR+ immune effectors (e.g., NK cells) to induce antibody‑dependent cellular cytotoxicity; may also trigger complement‑dependent cytotoxicity.
Monoclonal antibody that inhibits HER2 dimerization.
Humanized monoclonal antibody that binds the HER2 extracellular dimerization domain (subdomain II), blocking HER2 hetero-/homodimerization, thereby inhibiting downstream HER signaling (e.g., PI3K/AKT, MAPK), suppressing tumor cell proliferation and promoting apoptosis.
YES
DIRECT
Pertuzumab binds HER2 subdomain II and blocks HER2 dimerization, inhibiting downstream signaling and promoting apoptosis; its IgG1 Fc engages FcγR-bearing effector cells to mediate ADCC against HER2-expressing cells.
Antibody–drug conjugate (T‑DM1) combining trastuzumab with the microtubule inhibitor DM1.
HER2-targeted monoclonal antibody (trastuzumab) linked via a nonreducible thioether (MCC) to the microtubule inhibitor DM1. After binding HER2 and internalization, DM1 is released intracellularly to bind tubulin and disrupt microtubule dynamics, leading to cell-cycle arrest and apoptosis in HER2-overexpressing cells; the antibody also inhibits HER2 signaling and can mediate ADCC.
YES
DIRECT
The ADC binds HER2, is internalized, and releases the DM1 payload that disrupts microtubules, causing mitotic arrest and apoptosis; the antibody can also mediate ADCC.
Antibody–drug conjugate (T‑DM1) combining trastuzumab with the microtubule inhibitor DM1.
HER2-targeted monoclonal antibody (trastuzumab) linked via a nonreducible thioether (MCC) to the microtubule inhibitor DM1. After binding HER2 and internalization, DM1 is released intracellularly to bind tubulin and disrupt microtubule dynamics, leading to cell-cycle arrest and apoptosis in HER2-overexpressing cells; the antibody also inhibits HER2 signaling and can mediate ADCC.
NO
INDIRECT
T-DM1 targets HER2 on the cell surface; after HER2-mediated internalization, the DM1 payload binds beta‑tubulin to disrupt microtubules and induce mitotic arrest/apoptosis. Beta‑tubulin expression itself is not the determinant of targeting.
Investigational anti-CD20 monoclonal antibody (HS006) that depletes B cells to reduce autoantibody (e.g., anti-PLA2R) production and downstream immune complex/complement-mediated podocyte injury; administered intravenously.
Anti-CD20 monoclonal antibody that binds CD20 on B lymphocytes and depletes them via immune effector mechanisms (e.g., ADCC/CDC), lowering pathogenic autoantibody (e.g., anti-PLA2R) production and reducing immune complex/complement-mediated podocyte injury.
YES
DIRECT
Anti-CD20 IgG binds CD20 on B cells and triggers Fc-mediated ADCC/ADCP by immune effector cells and complement-dependent cytotoxicity (CDC), leading to B-cell lysis and depletion.